Brendan J Tunstall1, Irene Lorrai2,3, Sam A McConnell1, Katrina L Gazo1, Lia J Zallar1,4, Giordano de Guglielmo5, Ivy Hoang2, Carolina L Haass-Koffler6, Vez Repunte-Canonigo2, George F Koob1, Leandro F Vendruscolo1, Pietro Paolo Sanna2. 1. National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA. 2. Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA. 3. Department of Biomedical Sciences, University of Cagliari, Monserrato, Cagliari, Italy. 4. National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA. 5. Department of Psychiatry, University of California San Diego, La Jolla, CA, USA. 6. Center for Alcohol and Addiction Studies; Department of Psychiatry and Human Behavior; Department of Behavioral and Social Sciences, Brown University, Providence, RI, USA.
Abstract
AIMS: The development of novel and more effective medications for alcohol use disorder (AUD) is an important unmet medical need. Drug repositioning or repurposing is an appealing strategy to bring new therapies to the clinic because it greatly reduces the overall costs of drug development and expedites the availability of treatments to those who need them. Probenecid, p-(di-n-propylsulfamyl)-benzoic acid, is a drug used clinically to treat hyperuricemia and gout due to its activity as an inhibitor of the kidneys' organic anion transporter that reclaims uric acid from urine. Probenecid also inhibits pannexin1 channels that are involved in purinergic neurotransmission and inflammation, which have been implicated in alcohol's effects and motivation for alcohol. Therefore, we tested the effects of probenecid on alcohol intake in rodents. METHODS: We tested the effects of probenecid on operant oral alcohol self-administration in alcohol-dependent rats during acute withdrawal as well as in nondependent rats and in the drinking-in-the-dark (DID) paradigm of binge-like drinking in mice. RESULTS: Probenecid reduced alcohol intake in both dependent and nondependent rats and in the DID paradigm in mice without affecting water or saccharin intake, indicating that probenecid's effect was selective for alcohol and not the result of a general reduction in reward. CONCLUSIONS: These results raise the possibility that pannexin1 is a novel therapeutic target for the treatment of AUD. The clinical use of probenecid has been found to be generally safe, suggesting that it can be a candidate for drug repositioning for the treatment of AUD.
AIMS: The development of novel and more effective medications for alcohol use disorder (AUD) is an important unmet medical need. Drug repositioning or repurposing is an appealing strategy to bring new therapies to the clinic because it greatly reduces the overall costs of drug development and expedites the availability of treatments to those who need them. Probenecid, p-(di-n-propylsulfamyl)-benzoic acid, is a drug used clinically to treat hyperuricemia and gout due to its activity as an inhibitor of the kidneys' organic anion transporter that reclaims uric acid from urine. Probenecid also inhibits pannexin1 channels that are involved in purinergic neurotransmission and inflammation, which have been implicated in alcohol's effects and motivation for alcohol. Therefore, we tested the effects of probenecid on alcohol intake in rodents. METHODS: We tested the effects of probenecid on operant oral alcohol self-administration in alcohol-dependent rats during acute withdrawal as well as in nondependent rats and in the drinking-in-the-dark (DID) paradigm of binge-like drinking in mice. RESULTS:Probenecid reduced alcohol intake in both dependent and nondependent rats and in the DID paradigm in mice without affecting water or saccharin intake, indicating that probenecid's effect was selective for alcohol and not the result of a general reduction in reward. CONCLUSIONS: These results raise the possibility that pannexin1 is a novel therapeutic target for the treatment of AUD. The clinical use of probenecid has been found to be generally safe, suggesting that it can be a candidate for drug repositioning for the treatment of AUD.
Authors: William R Silverman; Juan Pablo de Rivero Vaccari; Silviu Locovei; Feng Qiu; Steven K Carlsson; Eliana Scemes; Robert W Keane; Gerhard Dahl Journal: J Biol Chem Date: 2009-05-05 Impact factor: 5.157
Authors: Roger J Thompson; Michael F Jackson; Michelle E Olah; Ravi L Rungta; Dustin J Hines; Michael A Beazely; John F MacDonald; Brian A MacVicar Journal: Science Date: 2008-12-05 Impact factor: 47.728
Authors: Walter Francesconi; Fulvia Berton; George F Koob; Pietro Paolo Sanna Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2009-08-12 Impact factor: 5.067
Authors: Mehdi Farokhnia; Christopher T Rentsch; Vicky Chuong; M Adrienne McGinn; Sophie K Elvig; Eliza A Douglass; Luis A Gonzalez; Jenna E Sanfilippo; Renata C N Marchette; Brendan J Tunstall; David A Fiellin; George F Koob; Amy C Justice; Lorenzo Leggio; Leandro F Vendruscolo Journal: Mol Psychiatry Date: 2022-09-20 Impact factor: 13.437
Authors: Leticia Gil de Biedma-Elduayen; Pablo Giménez-Gómez; Nuria Morales-Puerto; Rebeca Vidal; Carlos Núñez-de la Calle; María Dolores Gutiérrez-López; Esther O'Shea; María Isabel Colado Journal: Br J Pharmacol Date: 2022-03-07 Impact factor: 9.473
Authors: Laura B Ferguson; Shruti Patil; Bailey A Moskowitz; Igor Ponomarev; Robert A Harris; Roy D Mayfield; Robert O Messing Journal: Brain Sci Date: 2019-12-16